Cancer Biotherapy and Radiopharmaceuticals最新文献

{"title":"Small Animal Positron Emission Tomography Imaging of a Triple-Negative Breast Cancer Model Using the ⁶⁸Ga-Labeled pH (Low) Insertion Peptide-Like Peptide YJL-11.","authors":"Mingming Yu, Fengyu Wu, Yanqin Sun, Shuangshuang Song, Yuehua Chen","doi":"10.1089/cbr.2024.0230","DOIUrl":"10.1089/cbr.2024.0230","url":null,"abstract":"<p><p><b><i>Objectives:</i></b> To prepare a novel ⁶⁸Ga-labeled pH (low) insertion peptide-like peptide, YJL-11, and study its ability to be used as a probe for the diagnosis of triple-negative breast cancer (TNBC) via <i>in vivo</i> imaging of tumor-bearing nude mice. <b><i>Methods:</i></b> Circular dichroism (CD) analysis of YJL-11 was performed to assess its secondary structure. YJL-11 was labeled with ⁶⁸Ga, and the <i>in vivo</i> biodistribution of ⁶⁸Ga-YJL-11 in MDA-MB-231 xenograft mice was evaluated. This probe was then applied for small animal positron emission tomography (PET) imaging of tumor-bearing nude mice. <b><i>Results:</i></b> CD analysis of YJL-11 confirmed a typical pH-dependent transition in its secondary structure. The radiochemical yield of ⁶⁸Ga-YJL-11 was 75.5 ± 0.25%, and the radiochemical purity was 95.75 ± 0.15%. Biodistribution studies showed that the tumor uptake of ⁶⁸Ga-YJL-11 was significantly higher than in the control group, 1 and 2 h after injection. Small animal PET imaging results were consistent with the biodistribution data, showing clear images of the tumors and livers 1 and 2 h after injection of ⁶⁸Ga-YJL-11, whereas tumors were not detected in the control group. <b><i>Conclusion:</i></b> ⁶⁸Ga-YJL-11 was prepared with high radiochemical yield and can target TNBC tissues, indicating that it has great potential in the diagnosis of TNBC.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"389-397"},"PeriodicalIF":2.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Comment on \"IL-21 and IL-33 May Be Effective Biomarkers to Predict the Efficacy of PD-1 Monoclonal Antibody for Advanced Cholangiocarcinoma\".","authors":"Hinpetch Daungsupawong, Viroj Wiwanitkit","doi":"10.1089/cbr.2025.0039","DOIUrl":"10.1089/cbr.2025.0039","url":null,"abstract":"","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"441"},"PeriodicalIF":2.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Applications of Nanobodies in Biological Imaging.","authors":"Liangjü Sheng, Kai Sheng, Peng Lü","doi":"10.1089/cbr.2025.0005","DOIUrl":"10.1089/cbr.2025.0005","url":null,"abstract":"<p><p><b><i>Background:</i></b> Nanobodies (Nbs), derived from Camelidae heavy-chain antibodies, are single-domain fragments (15 kDa) with high antigen-binding specificity, enhanced tissue penetration, and low immunogenicity. These attributes address limitations of conventional antibodies, positioning Nbs as pivotal tools for targeted molecular imaging in diagnostics and therapeutics. <b><i>Methods:</i></b> Nbs are screened through phage/mRNA display or single B-cell sequencing, expressed in prokaryotic or yeast systems, and humanized via CDR grafting. Functional probes are engineered by conjugating Nbs with radionuclides (⁶⁸Ga, ^99mTc) or fluorophores (IRDye 800CW) for compatibility with PET, SPECT, NIRF, and ultrasound modalities. <b><i>Results:</i></b> Clinical trials validated Nb efficacy: ⁶⁸Ga-HER2-Nb PET/CT achieved tumor-specific uptake in HER2+ cancers (NCT04467515), while ^99mTc-PD-L1-Nb enabled quantitative SPECT-guided immunotherapy in NSCLC. NIRF-Nb conjugates (e.g., 11A4-800CW) enhanced intraoperative tumor delineation in murine models. Dual-targeted ultrasound microbubbles demonstrated multi-biomarker imaging via acoustic pressure modulation. <b><i>Conclusion:</i></b> Nbs advance biological imaging through superior resolution and rapid pharmacokinetics. Challenges persist in optimizing probe stability, minimizing immunogenicity, and scaling production. Future priorities include integrating multi-modal platforms, expanding applications to neurodegenerative disorders, and refining personalized diagnostic paradigms, underscoring their transformative potential in precision medicine.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"365-376"},"PeriodicalIF":2.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radioiodination of Silodosin with ¹³¹I as a Selective Drug for Prostate Imaging in Mice.","authors":"Mahmoud H Sanad, Safaa B Challan, Fatma Y Abdou, M El-Desawy, Heba M Essam","doi":"10.1089/cbr.2025.0015","DOIUrl":"10.1089/cbr.2025.0015","url":null,"abstract":"<p><p><b><i>Background:</i></b> Silodosin (Sild) is a selective α1A-adrenergic receptor antagonist effective in treating benign prostatic hyperplasia (BPH), a condition characterized by prostate enlargement, which leads to urinary dysfunction. <b><i>Objective:</i></b> This study aimed to radiolabel Sild with iodine-131 [¹³¹I]) using chloramine-T(Ch-T), optimized the process to achieve high radiochemical yields, and investigated the [¹³¹I]Sildodosin [¹³¹I]Sild) radiotracer in the prostate of murine models. <b><i>Methods:</i></b> Compared to a control group, biodistribution studies were conducted to evaluate the [¹³¹I]Sild radiotracer uptake in mice with BPH. Biochemical analyses were performed to assess serum prostate-specific antigen (PSA) levels, antioxidant enzyme activities catalase (CAT) and superoxide dismutase (SOD), and oxidative stress markers such as malondialdehyde (MDA) in both groups. <b><i>Results:</i></b> The [¹³¹I]Sild radiotracer exhibited a radiochemical yield of 93.7 ± 1.1% and maintained stability for up to 4 h in serum. Biochemical markers indicated an increase in PSA, lipid peroxidation, MDA levels, and protein content, with an increase in prostate weight in mice with BPH compared to the control group. Histopathological examination revealed disruption of tissue growth and a localized inflammatory response in BPH compared to the control. Biodistribution studies demonstrated significant uptake of the [¹³¹I]Silodosin radiotracer in BPH, with a value of 7.6 ± 0.18% ID/g at 120 min post-administration. <b><i>Conclusion:</i></b> The results suggest that [¹³¹I]Silodosin radiotracer holds potential as an imaging agent for chronic prostatic diseases, particularly BPH.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"410-425"},"PeriodicalIF":2.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapeutics in Clinical Trials for Cervical Cancer.","authors":"Umarani Yadagiri, Rahaman Shaik, Rajini Kolure, Tatheer Fatima, Huda Khan","doi":"10.1089/cbr.2025.0031","DOIUrl":"10.1089/cbr.2025.0031","url":null,"abstract":"<p><p>The fourth most common cause of cancer-related deaths in women is cervical cancer (CC) in the worldwide. Although there are differences in the accessibility of therapies across developed and developing nations, an improvement in survival rate has been observed in patients with precancerous lesions, thanks to the development of precancerous lesion identification and preventative human papillomavirus vaccination programs. Surgery can cure early-stage CC, but patients who experience a recurrence have a poor prognosis and few therapy alternatives. Recently, it has been demonstrated that the drug bevacizumab increases overall survival in this latter context when combined with chemotherapy as opposed to chemotherapy administered alone. Beyond this therapy regimen, there are no established treatments. Therefore, in this situation, new, effective treatments are desperately needed. Immunotherapy has been a revolutionary treatment.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"377-388"},"PeriodicalIF":2.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Danggui Buxue Decoction Combined with Borneol Improves Cyclophosphamide-Induced Myelosuppression by Inhibiting CDK2.","authors":"Kui Li, Ruoxia Wu, Ting Zhou, Jiaqing Xiong","doi":"10.1089/cbr.2024.0207","DOIUrl":"10.1089/cbr.2024.0207","url":null,"abstract":"<p><p><b><i>Objective:</i></b> This study explored the effective components and molecular targets of Danggui Buxue decoction (DBD) combined with borneol (DBD&Bor) in alleviating myelosuppression. <b><i>Methods:</i></b> A network pharmacology strategy was used to identify the active components and key targets of DBD&Bor in the context of myelosuppression. <i>In vivo</i>, the effects of the DBD&Bor and its effective components on cyclophosphamide (CTX)-induced myelosuppression in rats were evaluated through immunohematological analysis, histopathological analysis, and organ index analysis. <i>In vitro</i>, the impact of the effective components of DBD&Bor on CTX-stimulated apoptosis and cell cycle of K562 cells was analyzed using flow cytometry. Finally, the recovery experiment was used to verify further the relationship between the effective ingredient and the target. <b><i>Results:</i></b> Network pharmacology and ultrahigh-performance liquid chromatography-tandem mass spectrometry analysis revealed that the principal components, catechin, isorhamnetin, and erythrodiol, in DBD&Bor may function as a prospective antimyelosuppression compound. Animal experiments demonstrated that in DBD&Bor, catechin and isorhamnetin could reverse the reduction in hematopoietic stem cell number, the production of stem cell marker (C-kit), and blood cell counts induced by CTX in rats. In addition, CD3, CD4, and CD8α are significantly increased in peripheral blood mononuclear cells, and thymic and splenic pathological damage is significantly attenuated. Also, the improvement effect of catechin was more noticeable. Therefore, the authors chose catechin for further study. Nevertheless, <i>in vivo</i>, overexpression of <i>CDK2</i> negated the beneficial effects of catechin on myelosuppression. <i>In vitro</i> experiments demonstrated that catechin reduced CTX-induced apoptosis and cell cycle arrest in K562 cells by inhibiting <i>CDK2</i>. <b><i>Conclusion:</i></b> The primary component catechin in DBD&Bor inhibits the expression of <i>CDK2</i>, improving CTX-induced myelosuppression in rats and inhibiting apoptosis and cell cycle arrest in K562 cells.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"426-440"},"PeriodicalIF":2.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144310848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition of <i>KIAA0101</i> Expression Can Regulate Cell Proliferation and Apoptosis in Colon Cancer.","authors":"YanWei Yu, Xingchun Xiao, Fushu Jin","doi":"10.1089/cbr.2025.0108","DOIUrl":"https://doi.org/10.1089/cbr.2025.0108","url":null,"abstract":"<p><p><b><i>Background:</i></b> Colon cancer is a prevalent malignant tumor of digestive tract occurring in the colon. In the people with cancer, colon cancer is the third leading cause of deaths in the world. Basic research on colon cancer is of great importance to patients with the disease. <b><i>Methods:</i></b> In this article, the authors observed the <i>KIAA0101</i> expression in different types of cancers in public database (GEPIA2), found a gene network associated with <i>KIAA0101</i> in STRING database, and explored the correlation of these genes with <i>KIAA0101</i> at the expression level and the immune cells associated with the expression of <i>KIAA0101</i>. Then the authors detected the affection of <i>KIAA0101</i> to the proliferation and apoptosis of cancer cells and verified the consistency of <i>KIAA0101</i> expression in 31 tumor patient tissues using the database. <b><i>Results:</i></b> <i>KIAA0101</i> is differentially expressed in all kinds of tumor cells, and it shows high expression in colorectal cancer tissues. The authors found 10 genes related to <i>KIAA0101</i>, including <i>CDC20</i>, <i>TOP2A</i>, <i>CCNB2</i>, <i>CCNA2</i>, and so on, all of which show positive correlation with <i>KIAA0101</i> expression. In addition, the result of this study showed that <i>KIAA0101</i> expression had a positive correlation with the infiltration of Th1 and Th2 cells, with correlation coefficients of 0.371 and 0.627, respectively. <i>KIAA0101</i> gene shows high expression in both HCT15 and SW480 cell lines. Inhibition of <i>KIAA0101</i> expression can increase <i>caspase 3/7</i> activity in both HCT15 and SW480 cell lines, inhibit the proliferation ability of the two cell lines, and inhibit <i>Bcl-2</i> gene expression. <i>KIAA0101</i> also has tumor-suppressing effects in mice. The expression of <i>KIAA0101</i> gene also shows a significant increase in the tissues collected from 31 patients with tumor. <b><i>Conclusions:</i></b> Inhibition of <i>KIAA0101</i> expression can regulate cell proliferation and apoptosis in colorectal cancer.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low Serum Interleukin-6 Levels Enhance the Efficacy of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.","authors":"Yawei Wang, Ye Hu, Yi Qin, Xiangfeng Jin, Yandong Zhao","doi":"10.1177/10849785251360550","DOIUrl":"https://doi.org/10.1177/10849785251360550","url":null,"abstract":"<p><p><b><i>Background:</i></b> Neoadjuvant immunotherapy has become a standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC), but predictive biomarkers for treatment efficacy remain limited. This study investigates the role of serum interleukin-6 (IL-6) levels as a prognostic biomarker in patients receiving neoadjuvant immunotherapy for ESCC. <b><i>Methods:</i></b> A retrospective cohort study was conducted in 47 patients with locally advanced ESCC who underwent neoadjuvant immunochemotherapy followed by esophagectomy. Pretreatment serum levels of IL-6 and the combined positive score were analyzed. Pathological responses were evaluated using the College of American Pathologists Tumor Regression Grade system, and survival outcomes were assessed by Kaplan-Meier analysis. IL-6 knockout mice models were used to validate the impact of IL-6 on anti-PD-1 therapy efficacy. <b><i>Results:</i></b> Lower pretreatment serum IL-6 levels were significantly associated with better pathological response compared with higher IL-6 levels. Elevated IL-6 levels (>61.495 pg/mL) were identified as an independent risk factor for poorer disease-free survival and overall survival. IL-6 deficiency enhanced the efficacy of anti-PD-1 therapy in mice, reducing tumor burden compared with wild-type controls. Conversely, exogenous IL-6 administration attenuated anti-PD-1 effects. Mechanistically, lower serum IL-6 levels increased CD8⁺ T cell activation and decreased the regulatory T cell proportion during immunotherapy. <b><i>Conclusions:</i></b> Low serum IL-6 levels enhance the efficacy of neoadjuvant immunotherapy in locally advanced ESCC.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic and Prognostic Value of Combined Detection of Serum Protein Induced by Vitamin K Absence or Antagonist-II, Alpha-Fetoprotein, and Spliced Hepatitis B Virus in Hepatitis B Virus-Induced Hepatocellular Carcinoma.","authors":"Zhentian Guo, Haixing Mo, Yuqing Yuan, Wenjin Fu","doi":"10.1089/cbr.2025.0085","DOIUrl":"https://doi.org/10.1089/cbr.2025.0085","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;Objective:&lt;/i&gt;&lt;/b&gt; To demonstrate the diagnostic and prognostic value of combined detection of serum abnormal prothrombin II (PIVKA II), α-fetoprotein (AFP), and spliced variants of hepatitis B virus genomes (spHBV) in HBV-induced hepatocellular carcinoma (HCC). &lt;b&gt;&lt;i&gt;Materials and Methods:&lt;/i&gt;&lt;/b&gt; From March 2018 to May 2019, samples were collected from 125 patients with HBV-related hepatocellular carcinoma (HBV-HCC), 125 patients with pure HBV (HBV group), and 125 patients with HBV-induced cirrhosis (HBV cirrhosis group), all of whom were receiving treatment at the hospital. Serum levels of PIVKA-II, AFP, and spHBV were measured using an immunochemiluminescence detection system, a fully automated immunoassay analyzer, and a real-time quantitative polymerase chain reaction instrument, respectively. Kaplan-Meier method was applied to analyze relationship among serum PIVKA-II, AFP, spHBV, and prognosis of patients with HBV-HCC; cyclooxygenase (COX) risk regression analyzed factors affecting prognosis of patients with HBV-HCC; receiver operating characteristic (ROC) curve evaluated diagnostic and prognostic predictive efficacy of serum PIVKA-II, AFP, and spHBV alone or combined for HBV-HCC. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; The serum concentrations of PIVKA-II, AFP, and spHBV in the HBV-HCC group were significantly higher than those in the HBV cirrhosis group and the HBV group (all &lt;i&gt;p&lt;/i&gt; &lt; 0.05). The HBV cirrhosis group also showed significantly higher levels compared with the HBV group (&lt;i&gt;p&lt;/i&gt; &lt; 0.05). Serum PIVKA-II, AFP, spHBV, tumor number, tumor-node-metastasis (TNM) stage, and extrahepatic metastasis differed markedly between dead patients and surviving patients (&lt;i&gt;p&lt;/i&gt; &lt; 0.05). PIVKA-II, AFP, and spHBV in patients with HBV-HCC were related to tumor number, TNM staging, and extrahepatic metastasis (&lt;i&gt;p&lt;/i&gt; &lt; 0.05).The 36-month survival rate of patients with high-expression PIVKA-II was inferior to patients with low expression (&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 6.561, &lt;i&gt;p&lt;/i&gt; = 0.010); the 36-month survival rate of patients with high-expression AFP was inferior to patients with low expression (&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 4.789, &lt;i&gt;p&lt;/i&gt; = 0.029); and the 36-month survival rate of patients with high-expression spHBV was inferior to patients with low expression (&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 5.761, &lt;i&gt;p&lt;/i&gt; = 0.016). Multivariate logistic regression analysis showed that high expression of PIVKA-II, AFP, spHBV in serum, multiple tumors, TNM staging of stage III-IV, and extrahepatic metastasis were all risk factors for death in patients with HBV-HCC (&lt;i&gt;p&lt;/i&gt; &lt; 0.05). The area under the curve (AUC) of the combination of serum PIVKA-II, AFP, and spHBV in the diagnosis for HBV-HCC was markedly higher than PIVKA-II, AFP, and spHBV alone diagnosis (&lt;i&gt;p&lt;/i&gt; &lt; 0.05). The AUC predicted by the combination of serum PIVKA-II, AFP, and spHBV in predicting the prognosis of patients with HBV-HCC was markedly higher than that predicted by the three factors alone (&lt;i&gt;p&lt;/i&gt; ","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Avatar: Personalized Precision Radio-Genomic Theranostic Oncology.","authors":"J Harvey Turner","doi":"10.1089/cbr.2025.0152","DOIUrl":"https://doi.org/10.1089/cbr.2025.0152","url":null,"abstract":"<p><p>Creation of a virtual avatar of a patient with cancer has the potential to transform theranostics into a truly individualized precision treatment of specific cancers, which express targetable receptors. Each patient is unique. Their cancer molecular biology has its own inherent relationship to their genomic phenotype and the metabolomic and immunological milieu of their tumor. This singularity can be captured and simulated through generation of an avatar, incarnated by means of artificial intelligence collection, collation and analysis of personal radio-genomics, tumor pathology, and molecular biology data, in the form of a digital twin. The capacity to replicate these idiosyncratic individual interactions within a digital twin construct of such a virtual avatar allows contemplation of <i>ex vivo</i> prototypical design and testing of N-of-1 theranostic strategies in real time. Continuing follow-up and analysis of evolving data confers the opportunity to adapt treatments to predict tumor response of the cancer in the avatar in order to optimize clinical outcomes in the actual patient.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}